10-Q quarterly report · filed Nov 5, 2026

Solventum (SOLV) Q3 2026 10-Q Quarterly Report

Short answer

Solventum (SOLV) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.9B (down 7.0% year over year) with net income of −$12M.

Q3 2026 key financials · XBRL

Revenue
$1.9B
−7.0% YoY · −11.8% QoQ
Net income
−$12M
−100.9% YoY · −113.0% QoQ
Operating margin
3.4%
Gross margin
54.5%
EPS (diluted)
−$0.06
−100.8% YoY · −111.3% QoQ

Source: XBRL data from the Solventum (SOLV) Q3 2026 10-Q on SEC EDGAR. USD.

Solventum Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $1,949M, down 7.0% YoY from $2,096M, reflecting ERP-related customer destocking
  • Operating margin 3.5% vs 80.6% YoY, with $1.5B prior-year business-sale gain
  • Best segment Health Information Systems: sales up 3.3%, operating margin 41.7% vs 38.8%
  • Worst segment Dental Solutions: sales down 6.7%, operating margin 20.1% vs 25.7%
  • Cash $451M vs $878M at December 31, 2025, with $118M of $120M tariff refunds recovered

Risk Factors

  • Newly added strategic risk: health information systems review may fail to produce or complete a strategic alternative
  • Most material update: review creates customer and employee uncertainty while diverting management attention
  • Operational risk: review-related costs may arise regardless of transaction success
  • Financial risk: unsuccessful alternatives could adversely affect cash flows

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Solventum quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.